Key Takeaways
- Sequential revenue dip, structural margin recovery: Revenue fell 11% QoQ on export and spec chem weakness, but EBITDA margins improved ~200 bps YoY as input costs stabilized and capacity utilization rose.
- API volumes strong, exports constrained: Domestic API volumes grew ~18%, while export geographies faced USD shortages that slowed growth.
- Specialty chemicals the clear drag: China’s reopening flooded international markets with lower-priced products, and campaign-based product absence hit the segment YoY.
- Margin expansion promised through product mix and integration: Entry into dermatology and backward integration in H2 FY24 are expected to accelerate margins, with a quarterly exit target of 14.5%–15% EBITDA.
- What to watch next quarter: Whether the sequential margin improvement materializes as high-cost inventory clears, and whether spec chem demand stabilizes as guided.
Revenue Walk: What Drove the Quarter
- Top-line growth, but only YoY: Consolidated revenue grew 6.3% YoY, helped by normalizing input costs and working capital utilization. The sequential picture was weaker: revenue down 11% QoQ, with API revenue down ~17% sequentially.
- Volume story is split: API volumes grew ~18% YoY on domestic demand, but sequential volume declined in export and spec chem. Q4 is seasonally the biggest quarter, with heavy antibiotic buying in the domestic market that did not repeat in Q1.
- Formulations exports a bright spot: Export revenue in formulations rose sharply YoY, driven by a strategic push on regulatory filings. The company is shifting mix from lower-margin domestic CMO work toward export markets, where margins are better.
- Specialty chemicals hit from two sides: The segment declined YoY because a couple of campaign-based products were absent, and China reopened to dump product at lower prices into international markets. Demand from Latin America, Europe, and the U.S. also softened.
- Metformin capacity temporarily offline: The metformin facility was shut for part of the quarter for an expansion that has since completed, reducing volumes sold in Q1.
- Gliptins consolidating slowly: Post-patent, the market saw 20–30 players enter simultaneously; management expects consolidation to 3–4 players over 1–3 years, with backward integration helping market share gradually.
Adhish Patil: "we feel like in the current year, around 10%, we'll try to achieve, though it will be challenging because there has been negative rate variances as far as sales are concerned because as you know, that the input prices have gone down and so are the selling prices."
Margin Mechanics: Inventory Fog and the Recovery Path
- FIFO is masking real margins: Current sales orders and POs suggest margins have recovered, but high-cost inventory in the pipeline is depressing reported margins because the company uses FIFO accounting. Raw material prices declined only 2%–2.5% from March to June, with no decline in May and June.
- Input cost stability taking hold: Raw material prices are trending down, attributed to lower crude prices post the Russia-Ukraine spike and more suppliers than demand. Management sees no further volatility, with prices stable from May through June.
- Power and freight costs easing: Coal prices have fallen from ~INR11 to INR8.5 and are expected to decline further. Freight costs started improving from the December 2022 quarter onward.
- Sequential margin improvement expected: As high-cost inventory is consumed, margins should improve quarter by quarter, exiting Q4 FY24 at 14%–15% EBITDA.
- Product mix and backward integration as levers: Entry into dermatology and backward integration in H2 FY24, combined with stable input costs, are expected to accelerate margin expansion.
Adhish Patil: "Only problem is because all the FIFO techniques, inventory calculation is down FIFO basis, so that is impacting the overall margins of the company when we report it quarter-on-quarter basis. But otherwise, it seems like the margins should be back."
Capex Pipeline: Greenfield Bets and a Delayed Launch
- Two greenfield projects anchor the growth story: Backward integration plus spec chem, and dermatology, together carry total revenue potential of INR1,000–1,200 crores. First-year utilization in FY25 is projected at 30%–35%, ramping to ~60% in year two and ~80% thereafter.
- FY24 capex spend: The company plans to complete INR250–350 crores of capex this fiscal year, inclusive of maintenance capex. All major projects including Gujarat Saykha and Tarapur are scheduled for completion within FY24, with commercial operations starting in Q3.
- Next year’s capex lighter: If both the anti-diabetic and side-chain projects start, FY25 capex is expected at INR100–200 crores including maintenance.
- Anti-diabetic expansion delayed: The planned 2,000 tons per month anti-diabetic expansion has been pushed out and will likely be completed next year, because the company kept refining the process before launch.
- Brownfield additions near-term: A brownfield expansion was set for August completion, and a small brownfield expansion on OFD capacities is planned over the next six months.
- Salicylic acid: high confidence, no timeline: Management is confident in its piloted process and cites its floxacin import-substitution track record (from 95% imported to 80%–90% indigenous) as precedent. No policy measures are factored in, though any government support would be an extra advantage.
Adhish Patil: "We are confident about the process, what we have developed. We have done piloting also. And as of now, the margin is very high, but then we expect some price cuts from China, some reaction from China."
Segment & Market Dynamics
| Segment | Trend | Commentary |
|---|---|---|
| API (domestic) | ▲ Strong volume | ~18% volume growth driven by domestic demand; antibiotics saw heavy buying in Q4 that normalized in Q1. |
| API (export) | ▼ Constrained | USD shortages in some export geographies slowed growth. |
| Formulations (export) | ▲ Growing | Strategic regulatory filings drove a sharp YoY export revenue increase; mix shift from domestic CMO to higher-margin exports underway. |
| Specialty Chemicals | ▼ Weak | China dumping at lower prices, campaign-based product absence, and soft demand from LatAm, Europe, and the U.S. Q2 expected slightly better, Q3 better still with an additional product. |
| Metformin | ▬ Temporary dip | Facility shut for expansion during Q1; volumes expected to grow henceforth after 30% capacity increase to ~1,415 tons/month. |
| Gliptins | ▬ Gradual consolidation | Market crowded post-patent; consolidation to 3–4 players expected over 1–3 years, with backward integration helping share gains. |
Balance Sheet & Capital Actions
- Buyback approved: On 21 July 2023, the Board approved a buyback of 665,000 fully paid-up equity shares at INR900 per share, for an aggregate amount of up to INR59.85 crores via tender offer.
- Inventory reduction plan: Management is working to reduce inventory days, targeting pre-COVID levels on RM and WIP, which were slightly lower than current.
- EU GMP certificate received: The facility previously under an import alert has received an EU GMP certificate from European authorities; the company is using this to expedite the inspection process.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Quarterly EBITDA exit rate | At least 14.5%–15% | Q4 FY24 |
| FY24 revenue growth | ~10% value growth, assuming current prices, with high-teens volume growth | FY24 |
| FY24 capex completion | INR250–350 crores, all major projects completed; commercial ops from Q3 FY24 | FY24 |
| Sequential margin improvement | Margins to improve quarter by quarter as high-cost inventory clears | Each quarter through Q4 FY24 |
| Spec chem recovery | Q2 slightly better than Q1; Q3 better still with an additional product | Q2 and Q3 FY24 |
| Greenfield utilization (year 1) | 30%–35% utilization of the two greenfield projects | Q1 FY25 |
| FY25 capex | INR100–200 crores including maintenance, if anti-diabetic and side-chain projects start | FY25 |
| FY25 EBITDA margin | 15%–16%, per an analyst’s math that management selected as reasonable; first year of new products limits upside | FY25 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Consolidated revenue | ₹661.7 cr, +6.3% YoY |
| Standalone revenue | ₹591.6 cr, +7.3% YoY; 86% of consolidated revenue |
| EBITDA | ₹84.7 cr, +26% YoY |
| EBITDA margin | 12.8%, improved ~200 bps YoY |
| PAT | ₹48 cr, +38% YoY |
| PAT margin | 7.3% |
| Domestic revenue growth (standalone) | ~13.6% YoY |
| Export revenue growth (standalone) | ~-4% YoY |
| API volume growth | ~18% YoY, aggregate basis |
| API price change | -8% to -9% YoY, aggregate basis |
| Formulation segment revenue | ₹89.9 cr, ~14% of total revenue; 67% from exports |
| Capex incurred in Q1 | ₹48 cr |
| Full-year capex guidance | ₹250 cr to ₹350 cr, inclusive of maintenance capex |
| Consolidated gross debt | ₹590 cr |
| Buyback | ₹59.85 cr aggregate amount, 6,65,000 shares at ₹900 per share |
| FY24 revenue growth guidance | ~10% value growth, assuming current prices and high-teens volume growth |
| FY24 exit EBITDA margin guidance | 14% to 15% by Q4 FY24 |